Health & Pharma

Novo Nordisk & Hims & Hers Partner to Expand GLP-1 Access Through Telehealth

Novo Nordisk and telehealth provider Hims & Hers have entered a new partnership that will allow patients to access Novo’s GLP-1 medications through the Hims online care platform. The agreement follows previous disagreements between the two companies and signals a meaningful shift toward collaboration between drug manufacturers and digital health providers.

Branded GLP-1 Treatments Now Available via Hims Platform

Under the arrangement, Hims will begin offering Novo’s branded treatments for diabetes and weight management, including Ozempic and Wegovy, to patients in the United States. These medications will be available through a self-pay model intended to remain competitive with other telehealth services.

“

The partnership could expand the reach of Novo’s medications by connecting them with Hims’ large digital patient base.

— Industry Analysts

Shift Away from Compounded GLP-1 Products

As part of the partnership, Hims will stop broadly promoting compounded GLP-1 products and will instead guide patients toward FDA-approved options when appropriate. Compounded medications may still be used in certain cases if a patient’s medical needs cannot be met with commercially available therapies.

Key Takeaways

Hims & Hers will offer Ozempic and Wegovy via a self-pay telehealth model.
Hims will cease broad promotion of compounded GLP-1 products.
Novo Nordisk drops patent litigation against Hims as part of the settlement.
The deal expands Novo’s reach into Hims’ large digital patient base.
Regulators are increasing scrutiny of compounded weight-loss medications.

Legal Settlement & Regulatory Context

The agreement also settles ongoing legal issues between the companies, with Novo dropping litigation related to patent concerns involving similar products previously marketed by Hims. Industry analysts believe the partnership could significantly expand the reach of Novo’s medications by connecting them with Hims’ large digital patient base.

The move also comes at a time when regulators are paying closer attention to the marketing and use of compounded weight-loss medications, while continuing to emphasize the role of approved therapies and compliant compounding practices.

Tags: Novo NordiskHims & HersGLP-1OzempicWegovyTelehealthDigital Health

Ready To Partner for Lasting Quality Solutions?

Let's discuss how Amicus can support your organization's compliance, validation, and quality objectives. Whether you're launching a new facility, remediating FDA findings, or building sponsor quality systems—we're here to help.

Book a Consultation